[{"orgOrder":0,"company":"Remedium","sponsor":"Tufts University","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"RMD 1101","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Remedium","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Remedium \/ Tufts University","highestDevelopmentStatusID":"4","companyTruncated":"Remedium \/ Tufts University"}]

Find Clinical Drug Pipeline Developments & Deals by Remedium

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EASL Congress
                          Not Confirmed
                          EASL Congress
                          Not Confirmed

                          Details : Through this partnership, Remedium aims to characterize the functionality of its lead candidate RMD 1101, in a range of in vitro, ex vivo, and in vivo efficacy models that will help to advance it toward IND.

                          Product Name : RMD 1101

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          September 15, 2021

                          Lead Product(s) : RMD 1101

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Preclinical

                          Sponsor : Tufts University

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank